Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2016 - 2018)

Historic Gains from Sales and Divestitures for Vanda Pharmaceuticals (VNDA) over the last 8 years, with Q1 2018 value amounting to $475367.0.

  • Vanda Pharmaceuticals' Gains from Sales and Divestitures rose 3679.47% to $475367.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $475367.0, marking a year-over-year increase of 3679.47%. This contributed to the annual value of $362313.0 for FY2017, which is 2594.92% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $475367.0 for Q1 2018, which was up 3679.47% from $362313.0 recorded in Q4 2017.
  • In the past 5 years, Vanda Pharmaceuticals' Gains from Sales and Divestitures registered a high of $475367.0 during Q1 2018, and its lowest value of $209562.0 during Q1 2014.
  • Its 5-year average for Gains from Sales and Divestitures is $282623.5, with a median of $287666.0 in 2016.
  • Data for Vanda Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY increase of 3747.54% (in 2014) and a maximum YoY decrease of 416.33% (in 2014) over the last 5 years.
  • Over the past 5 years, Vanda Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $209562.0 in 2014, then grew by 10.27% to $231093.0 in 2015, then rose by 24.48% to $287666.0 in 2016, then increased by 25.95% to $362313.0 in 2017, then surged by 31.2% to $475367.0 in 2018.
  • Its Gains from Sales and Divestitures stands at $475367.0 for Q1 2018, versus $362313.0 for Q4 2017 and $356127.0 for Q3 2017.